Omalizumab in the Treatment of Severe Allergic (IgE-mediated) Asthma: An Update on Recent Developments

Clinical and Translational Allergy - United Kingdom
doi 10.1186/2045-7022-3-s1-o12
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

ABS37: Add-On Omalizumab Improves Asthma Control Across Multiple Measures of Response in Patients With Severe Persistent Allergic (IgE-mediated) Asthma

Primary Care Respiratory Journal
2006English

P170 Long-Term Effectiveness of Omalizumab in Patients With Severe Persistent Allergic (IgE-mediated) Asthma: UK Centre Real-Life Experience

Thorax
PulmonaryRespiratory Medicine
2013English

Recent Developments in Bronchial Thermoplasty for Severe Asthma

Journal of Asthma and Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2019English

Appropriate Selection for Omalizumab Treatment in Patients With Severe Asthma?

European Clinical Respiratory Journal
2017English

Real-Life Effectiveness of Omalizumab in Severe Allergic Asthma Above the Recommended Dosing Range Criteria

Pediatrics
Child HealthPediatricsPerinatology
2017English

Effect of Omalizumab on Lung Function and Eosinophil Levels in Adolescents With Moderate-To-Severe Allergic Asthma

Annals of Allergy, Asthma and Immunology
Respiratory MedicinePulmonaryAllergyImmunology
2020English

Omalizumab Treatment in Brittle Asthma

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2014English

Effects of Omalizumab on Blood Eosinophil Numbers in Patients With Allergic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Biologic Therapy in Severe Asthma: An Update

Archives of Asthma, Allergy and Immunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy